ArticleBMC oral health2026
Exosomes derived from stem cells from apical papilla reduce Th17 cell differentiation and hyposalivation in a murine model of Sjögren's disease.
Article in BMC oral health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundSjögren’s disease (SjD) is a chronic autoimmune disease that is characterized by progressive lymphocyte infiltration and a decrease in the secretory function of the salivary glands. Mesenchymal stem cell (MSCs) transplantation has shown great potential in the treatment of SjD. Exosomes are one of the key paracrine factors that allow MSCs to perform their functions, and are more stable and safer than MSCs. Stem cells from apical papilla (SCAP), a kind of dental stem cells that are derived from the neural crest, have a wide range of immunoregulatory properties. However, the roles of exosomes derived from SCAP (SCAP-Exo) in the treatment of SjD are not clear. This study investigated the effects of SCAP-Exo on ameliorating hyposalivation in a murine model of SjD and the underlying mechanisms.
methodsSCAP was extracted from human apical papilla tissue. Then, SCAP-Exo were isolated and characterized by western blotting, transmission electron microscopy and nanoparticle tracking analysis. SCAP-Exo were systemically infused into murine models of SjD via the tail vein. The saliva flow rate tests and H&E staining were performed to detect the salivary secretion and pathologic changes of submandibular glands. T helper 17 (Th17) cells percentage and interleukin-17 (IL-17) levels changes were detected by flow cytometry and enzyme-linked immunosorbent assays (ELISA). PIWI-interacting RNA (piRNA) array analysis was conducted to determine the piRNA expression profiles of SCAP-Exo and screen for piRNAs associated with Th17 cell differentiation pathway. A luciferase reporter assay was performed to reveal the possible effect of the exosomal hsa-piR-188154 on interleukin-6 receptor (IL-6R) mRNA. Furthermore, the molecular mechanism by which hsa-piR-188154 regulated Th17 cell differentiation in vitro was tested by flow cytometry, ELISA, and reverse transcription-quantitative polymerase chain reaction.
resultsWe found that SCAP-Exo transplantation successfully improved saliva secretion, alleviated lymphocyte infiltration in the submandibular glands and reduced the proportion of Th17 cells in SjD mice. Mechanistically, hsa-piR-188154 was enriched in SCAP-Exo; a luciferase reporter assay demonstrated that hsa-piR-188154 directly targeted the IL-6R mRNA 3’ untranslated region. Furthermore, we revealed that hsa-piR-188154 inhibited Th17 differentiation and downregulated the level of IL-17 A in the supernatant and the expression levels of Th17-related genes in vitro.
conclusionThis study demonstrated that SCAP-Exo had a superior therapeutic effect on SjD by inhibiting Th17 cell differentiation. These data suggested that SCAP-Exo could be used in a cell-free approach for the clinical treatment of autoimmune disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.